\-\ Texto\\:\\ \ \(0\)\
\-\ macrocephay\ \(0\)\
\-\ diffuse\\,\\ symmetric\\ involvement\\ of\\ cerebral\\ white\\ matter\ \(0\)\
\-\ subcortical\\ white\\ matter\\ preferentially\\ affected\\ early\ \(0\)\
\-\ no\\ contrast\\ enhancement\ \(2\)\
\-\ mrs\\:\\ elevation\\ of\\ naa\ \(0\)\
\-\ canavan\\ disease\ \(0\)\
\-\ alexander\\ disease\ \(0\)\
\-\ canavan\\ disease\ \(0\)\
\-\ metachromatic\\ leukodystrophy\ \(1\)\
\-\ 2\\ y\\.o\\.\\ girl\\ whose\\ parents\\ noted\\ irritability\\ in\\ early\\ neonatal\\ course\\.\\ \\ this\\ improved\\ by\\ 5\\ months\\ of\\ age\\ when\\ patient\\ was\\ noted\\ to\\ be\\ hypotonic\\.\ \(0\)\
\-\ she\\ was\\ also\\ diagnosed\\ in\\ infancy\\ with\\ cortical\\ blindness\\ and\\ has\\ developmentally\\ delay\\.\\ \\ head\\ size\\ noted\\ to\\ be\\ large\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ canavan\\:\\ 0\\.3900029243608741\ \(0\)\
\-\ macrocephay\\:\\ 0\\.2040717609396323\ \(0\)\
\-\ noted\\:\\ 0\\.20297151938075186\ \(0\)\
\-\ metachromatic\\:\\ 0\\.19500146218043704\ \(0\)\
\-\ matter\\:\\ 0\\.194324492706245\ \(0\)\
\-\ mrs\\:\\ 0\\.18856598279485687\ \(0\)\
\-\ early\\:\\ 0\\.18396660415199406\ \(0\)\
\-\ alexander\\:\\ 0\\.18357423717696322\ \(0\)\
\-\ hypotonic\\:\\ 0\\.18357423717696322\ \(0\)\
\-\ preferentially\\:\\ 0\\.17604731648933922\ \(0\)\
\-\ naa\\:\\ 0\\.17604731648933922\ \(0\)\
\-\ leukodystrophy\\:\\ 0\\.17604731648933922\ \(0\)\
\-\ developmentally\\:\\ 0\\.17306020465008143\ \(0\)\
\-\ white\\:\\ 0\\.16838328655615484\ \(0\)\
\-\ irritability\\:\\ 0\\.16219934177679662\ \(0\)\
\-\ disease\\:\\ 0\\.1606949613612878\ \(0\)\
\-\ infancy\\:\\ 0\\.16054153834456375\ \(0\)\
\-\ whose\\:\\ 0\\.157554426505306\ \(0\)\
\-\ blindness\\:\\ 0\\.157554426505306\ \(0\)\
\-\ subcortical\\:\\ 0\\.13762326487282586\ \(0\)\
\-\ neonatal\\:\\ 0\\.13492480360924552\ \(0\)\
\-\ parents\\:\\ 0\\.13297834960133526\ \(0\)\
\-\ delay\\:\\ 0\\.11701131574949518\ \(0\)\
\-\ elevation\\:\\ 0\\.11633678899186209\ \(0\)\
\-\ improved\\:\\ 0\\.1132392072528733\ \(0\)\
\-\ symmetric\\:\\ 0\\.1093543359208951\ \(0\)\
\-\ affected\\:\\ 0\\.10495390515104212\ \(0\)\
\-\ be\\:\\ 0\\.10353031364715284\ \(0\)\
\-\ course\\:\\ 0\\.09425752911616508\ \(0\)\
\-\ diagnosed\\:\\ 0\\.09243523884552443\ \(0\)\
\-\ involvement\\:\\ 0\\.0923592791486532\ \(0\)\
\-\ cortical\\:\\ 0\\.09161353978577691\ \(0\)\
\-\ girl\\:\\ 0\\.08951480398330451\ \(0\)\
\-\ was\\:\\ 0\\.08894477476635736\ \(0\)\
\-\ cerebral\\:\\ 0\\.08840746917491919\ \(0\)\
\-\ size\\:\\ 0\\.0864028353962833\ \(0\)\
\-\ age\\:\\ 0\\.08011309013677577\ \(0\)\
\-\ diffuse\\:\\ 0\\.08002553578142876\ \(0\)\
\-\ when\\:\\ 0\\.07708215828500536\ \(0\)\
\-\ head\\:\\ 0\\.07610776164100146\ \(0\)\
\-\ she\\:\\ 0\\.07596155125622954\ \(0\)\
\-\ of\\:\\ 0\\.07491651762381356\ \(0\)\
\-\ months\\:\\ 0\\.07427773909041392\ \(0\)\
\-\ enhancement\\:\\ 0\\.07344850741052256\ \(0\)\
\-\ large\\:\\ 0\\.06393756289850368\ \(0\)\
\-\ to\\:\\ 0\\.06380311993344662\ \(0\)\
\-\ in\\:\\ 0\\.063489081109275\ \(0\)\
\-\ contrast\\:\\ 0\\.062001753720313454\ \(0\)\
\-\ also\\:\\ 0\\.06002278973831255\ \(0\)\
\-\ has\\:\\ 0\\.05828727021212072\ \(0\)\
\-\ by\\:\\ 0\\.05418943605446296\ \(0\)\
\-\ this\\:\\ 0\\.043848146542216505\ \(0\)\
\-\ patient\\:\\ 0\\.04150422995764435\ \(0\)\
\-\ no\\:\\ 0\\.041496423253941116\ \(0\)\
\-\ and\\:\\ 0\\.02636847437347147\ \(0\)\
\-\ with\\:\\ 0\\.024987093408414054\ \(0\)\
